Canvas Medical vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Modern cloud-native EHR for direct primary care and value-based care organizations; API-first architecture replacing legacy systems competing with athenahealth and Elation Health.
About
Canvas Medical is a cloud-native electronic health record (EHR) platform designed specifically for modern primary care practices — combining clinical documentation (notes, orders, prescriptions), care management (population health tracking, chronic disease programs, care gap identification), billing and revenue cycle, and patient communication in an integrated system built on a contemporary technical architecture. Founded in 2015 in San Francisco, Canvas Medical targets independent primary care practices, direct primary care (DPC) practices, and value-based care organizations frustrated with legacy EHR systems.\n\nCanvas Medical's technical approach differs from legacy EHRs (Epic, athenahealth, eClinicalWorks) which were built in the early 2000s — Canvas uses a modern, API-first architecture that makes integration with third-party tools straightforward, and its workflow design reflects current clinical practice patterns rather than 1990s paper-chart workflows. The platform is particularly popular with DPC (direct primary care) practices that operate on membership subscription models, where the EHR needs to support high-touch patient communication and proactive care rather than just fee-for-service billing. Canvas also serves value-based care organizations where population health management tools matter.\n\nIn 2025, Canvas Medical competes with athenahealth, Modernizing Medicine, Elation Health, and DrChrono for ambulatory EHR market share in the primary care segment. The EHR market is mature but experiencing disruption pressure as smaller, newer entrants offer more modern experiences to independent practices that Legacy systems with dated UX can't match. The Canvas SDK allows developers to build custom workflow integrations, positioning Canvas as a platform rather than a closed system. The 2025 strategy focuses on growing with DSC and value-based care organizations scaling their primary care networks, deepening AI-powered clinical documentation (ambient note generation), and expanding the developer ecosystem built on Canvas's open API.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.